NeuroMab™ Anti-Granulin BBB Shuttle Antibody(NRZP-1022-ZP3957)

Figure 1 shows the specificity of the GEP antibody by Western blot analysis.

Figure 2 shows the localization of GEP in human liver tissue.

(A) Expression of GEP was detected in neoplastic hepatocytes (shown as brown staining), but not in other cell types of the tumor component (40X magnification). (B) Nontumorous liver tissue adjacent to the tumor (40X magnification) shows no GEP signal in the nontumorous hepatocytes.

Figure 3 shows the serum GEP concentrations of 72 healthy donors, 38 chronic hepatitis B patients and 107 HCC patients.

Figure 4 shows the receiver operating characteristic curve analysis of serum GEP performance (thick solid line). "Sensitivity" (fraction of true positives) is plotted against "1-Specificity" (fraction of false positives).

Figure 5 shows that in vitro treatment with A23 leads to inhibition of cell growth in a dose-dependent manner.

Figure 6 shows growth inhibition of Hep3B tumor xenografts in nude mice. Dose-dependent effects of twice-weekly treatment with A23 in established Hep3B tumors. Antibody A23 was injected intraperitoneally as A23-50 μg (■*■) or A23-100 μg (•), and PBS was used as a control (■). Compared with PBS control, the difference is significant at *P<0.05 and **P<0.005 levels.

Figure 7 shows the serum profile of mice on day 31 after A23 treatment. A) A23 concentration. B) GEP concentration.

Figure 8 shows A) Histological examination of Hep3B xenografts at 200x magnification on day 31 after A23 treatment. B) Histological examination of non-neoplastic liver at day 31 after A23 treatment at 20X magnification.

Figure 9 is the analysis of the proliferation and apoptosis of A23 in Hep3B tumors. A) Tumor cell proliferation in xenografts was assessed by Ki-67 staining. B) Apoptosis of tumor cells was assessed by TUNEL assay.

Figure 10 shows the effect of A23 on Hep3B xenografts.

Total xenograft lysates (20 μg) were immunoblotted with the indicated phospho-specific antibodies against phospho-p44/42 MAPK (Thr202/Tyr04) and phospho-AKT (Ser473) antibodies.